Health · 9 June 2026
GSK buys US cancer drug firm for $10.6 billion
GSK just made its biggest ever purchase, spending $10.6 billion on a US company that makes new cancer treatments. The British drugmaker bought Nuvalent, a Boston-based biotech firm, to get two late-stage lung cancer drugs currently awaiting US approval. These potential blockbuster treatments, zidesamtinib and neladalkib, could launch later this year if approved by the FDA.
Reported by Guardian · How we write briefs